
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vevoctadekin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Fred Hutchinson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
ST-067 with CD19 CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma
Details : Vevoctadekin is a Protein drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 01, 2025
Lead Product(s) : Vevoctadekin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Fred Hutchinson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable

Simcha Starts Studies Of ST-067 in Hematological Disorders
Details : ST-067 (vevoctadekin) is a decoy-resistant interleukin-18 stimulator, which is currently being evaluated for the treatment of patients with acute myeloid leukemia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 05, 2024

ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Details : Vevoctadekin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 19, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Interleukin-18
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Fred Hutchinson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Interleukin-18 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 09, 2024
Lead Product(s) : Interleukin-18
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Fred Hutchinson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : JANSSEN BIOTECH
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Simcha Therapeutics Licenses Decoy-Resistant IL-18 for Cell Therapy
Details : Under the terms of the agreement, Janssen will develop, manufacture, and commercialize CAR T-based cell therapy candidates with Simcha’s novel proprietary DR-18 for a set number of programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 08, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : JANSSEN BIOTECH
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vevoctadekin,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to evaluate clinical safety and benefits of ST-067, Simcha’s decoy resistant IL-18 agent, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with solid tumors.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
April 05, 2023
Lead Product(s) : Vevoctadekin,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vevoctadekin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : BVF Partners
Deal Size : $40.0 million
Deal Type : Series B Financing
Details : In addition, the Company has dosed the first patient in the Phase 1 portion of a first-in human multi-center Phase 1/2 clinical trial of its first drug candidate ST-067, a first-in-class “decoy-resistant” Interleukin-18 variant.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
January 27, 2022
Lead Product(s) : Vevoctadekin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : BVF Partners
Deal Size : $40.0 million
Deal Type : Series B Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ST-067
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Details : ST-067 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 08, 2021
Lead Product(s) : ST-067
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DR-18
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oral presentation and poster detail DR-18’s ability to re-animate exhausted NK cells, bias differentiation of T cells toward highly active effectors and expand the population of critical immune cells inside the tumor microenvironment.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 24, 2020
Lead Product(s) : DR-18
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vevoctadekin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : WuXi AppTec
Deal Size : $25.0 million
Deal Type : Series A Financing
Simcha debuts with $25M to advance custom-built IL-18 for cancer
Details : Simcha’s lead program involves a customized variant of interleukin-18 (IL-18), a cytokine with potent antitumor effects, developed in the lab of Scientific Founder Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology at the Yale School of Medi...
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
June 24, 2020
Lead Product(s) : Vevoctadekin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : WuXi AppTec
Deal Size : $25.0 million
Deal Type : Series A Financing
